%0 Journal Article %A DONATELLA GAMBINI %A ELISA LOCATELLI %A UMBERTO GIANELLI %A CLAUDIA BAREGGI %A BARBARA GALASSI %A ROBERTO VISINTIN %A SARA MASSIRONI %A PAOLO G. DELL'ORTO %A MAURIZIO TOMIROTTI %T Sunitinib-induced Complete Response in Metastatic Renal Cancer Expressing Neuroendocrine Markers: A New Predictive Factor? %D 2014 %J Anticancer Research %P 7361-7365 %V 34 %N 12 %X Background: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma. Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority. Case Report: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor. Conclusion: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm. %U https://ar.iiarjournals.org/content/anticanres/34/12/7361.full.pdf